• New study of over 350,000 patients reveals significant gaps in lung nodule management, with approximately two-thirds receiving no clinical work-up after nodule discovery.
• Research presented at ISPOR 2025 shows concerning rates of mismanagement, with 60% of biopsies performed on benign nodules and 35% of malignant nodules receiving only follow-up CT scans.
• Real-world data from a safety-net hospital demonstrates how Biodesix's Nodify Lung® testing can guide clinical decisions through actionable results in pulmonary nodule risk stratification.